the aid library

LIST OPTIONS

Filter

11065

Download (521)

View PDF (1537)

Spousal Violence and HIV: Exploring the Linkages in Five Sub-Saharan African Countries

MacQuarrie, Kerry L.D., Rebecca Winter, and Sunita Kishor ICF International (2013) C2

DHS Analytical Studies No. 36

Download (793)

View PDF (1416)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

Download (344)

View PDF (370)

Mental Health in the times of COVID-19 Pandemic

National Institute of Mental Health & Neurosciences, Bengaluru India; Dept. of Psychiatry (2020) CC

Guidance for General Medical and Specialised Mental Health Care Settings

Download (287)

View PDF (302)

Consolidated strategic information guidelines for HIV in the health sector. Executive Sumary

World Health Organization (2020) C_WHO

Driving Impact through Programme Monitoring and Management These guidelines – an update to the World Health Organization’s 2015 publication Consolidated strategic information guidelines – present a set of essential aggregate indicators and guidance on choosing, collecting and systematically ... more

Download (259)

View PDF (242)

Global Epidemiological Surveillance Standards for Influenza

World Health Organization WHO (2013) C_WHO

Download (375)

View PDF (705)

Haiti: Hurricane Matthew - Situation Report No. 22 (16 November 2016)

UN Office for the Coordination of Humanitarian Affairs (2016) C1

Main Points The delivery of humanitarian assistance is expected to slow down significantly over the next seven to ten days in anticipation of the electoral process and limited availability of transport and security assets. The percentage of extremely food-insecure people who have recei... more

Download (495)

View PDF (624)

Universal Access to HIV/AIDS, Tuberculosis and Malaria Services by A United Africa by 2010

African Union; (2006) C2

Special summit of African Union on HIV and Aids, Tuberculosis and Malaria (atm) Abuja, Nigeria 2–4 may, 2006Sp/Assembly/ATM/2 (I), Rev.3 Abuja call for accelerated action towards universal access to HIV and Aids, Tuberculosis and Malaria services in Africa

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (330)

View PDF (485)

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (379)

View PDF (380)

Teachers for All: Inclusive Teaching for Children with Disabilities Collaborating globally to promote Inclusive Development

Ingrid Lewis and Sunit Bagree International Disability and Development Consortium’s Inclusive Education Task Group (2013) CC

Download (1522)

View PDF (1275)

The Haiti Health Sector Directory: U.S.-Based Implementers Working in Haiti

USAID, Synergie Project (2003) C1

Download (257)

View PDF (247)

Statement to African Union Member States on the deployment of the AstraZeneca COVID-19 Vaccine to the continent and concerns about adverse event reports coming from Europe

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC

19 March 2021

Download (611)

View PDF (1188)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (277)

View PDF (285)

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Download (308)

View PDF (431)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed.

Download (475)

View PDF (701)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more